Europe Accelerates RevMed Drug Review Amid Mixed Biotech News

European regulators will accelerate their review of a drug developed by RevMed, according to a report from STAT News. The decision marks a procedural step forward for the company's application in the region.

In other biotech developments, data for a GLP-1 pill from Kailera has raised concerns. The nature of these concerns was not detailed in the report.

Separately, the U.S. Food and Drug Administration cleared an autoimmune therapy from Vera. The clearance allows the company to move forward with its development plans.